Brief: Vbi Vaccines And Agenus Announce Collaboration To Evaluate Vbi-1901 In Combination With Anti-Pd-1 Balstilimab In A Phase 2 Study In Primary Glioblastoma Patients
12/10/2022 13:07
Oct 12 (Reuters) - Agenus Inc AGEN.O :
* VBI VACCINES AND AGENUS ANNOUNCE COLLABORATION TO EVALUATE
VBI-1901 IN COMBINATION WITH ANTI-PD-1 BALSTILIMAB IN A PHASE 2
STUDY IN PRIMARY GLIOBLASTOMA PATIENTS
* VBI VACCINES INC- RANDOMIZED, CONTROLLED EVALUATION AS
PART OF
INSIGHT ADAPTIVE PLATFORM TRIAL EXPECTED TO INITIATE AROUND
YEAR-END 2022
* VBI VACCINES INC- RANDOMIZED, CONTROLLED EXTENSION STUDY
OF
VBI-1901 IN RECURRENT GBM PATIENTS EXPECTED TO INITIATE Q4 2022
Source text for Eikon: ID:nBw3D2BGYa
Further company coverage: AGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VBI Vaccines
See all newsBrief: VBI Vaccines Provides Update On Its Restructuring Proceedings
Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
VBI Vaccines Inc reports results for the quarter ended in March - Earnings Summary
Brief: VBI Vaccines Says Entered At Market Offering Deal For Gross Proceeds Of Up To $8.5 Mln
Brief: VBI Vaccines Q1 Adjusted EPS USD -0.55